DM Management in Elderly- What are the glucose targets?
|
|
- Earl Mitchell
- 8 years ago
- Views:
Transcription
1 DM Management in Elderly- What are the glucose targets? AFSHAN ZAHEDI, BASC, MD, FRCP(C) ENDOCRINOLOGY WOMEN S COLLEGE HOSPITAL ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF TORONTO NOVEMBER 2, 2011
2 Disclosures No Financial interest or investment in any Pharmaceutical company Advisory Boards for Amgen, Eli Lilly, GSK, Merck, Medtronics, Novartis, Novo- Nordisk, and Sanofi-Aventis CME programs for Amgen, Bristol-Myers Squibb, Eli Lilly, GSK, Merck, Novo- Nordisk, Novartis, Pfizer and Sanofi-Aventis
3 Objectives Differentiate aspects of DM in Geriatric population Review the current evidence on relation of glycemic control and DM complications Review current International Guidelines Suggest appropriate glycemic targets for geriatric patients Review Type 2 Diabetes treatment options in elderly Discuss the risks & the importance of eliminating hypoglycemia in geriatric patients
4 Prevalence of DM Prevalence of DM rises with age and higher in men than in women. 15 % of women and 20 % men over 75 have diagnosed diabetes and this number increases to 25% in ethnic groups. 1 out of 4 residents of LTC in Ontario have diabetes Aging population & immigration from areas with highest prevalence of diabetes in the world 1.Ontario Diabetes Database, 2. Diabetes Care 1998;21: Diabetes in Ontario; An ICES Practice Atlas 2003
5 Rational for Glycemic Management in Elderly Elderly with Diabetes have higher rates of: Functional disability Premature death Coexisting illness Hypertension Coronary heart disease Stroke JAGS 51:S
6 Rational for Glycemic Management in Elderly Increase in common Geriatric Syndromes is seen in older patients with diabetes: Cognitive impairment Urinary incontinence Injurious falls Persistent pain Depression Polypharmacy JAGS 51:S , Diab Care 20: , Diab Med 1:S41, 1998
7 Barriers in setting Glycemic Targets in Geriatric Population Variable life expectancies Clinical heterogeneity Functional heterogeneity Lack of Grade A evidence Exclusion of Frail Elderly from large RCTs Individualize Goals for DM management
8 Main Goals of Treatment Improvement of quality of life Prevention of onset of ACUTE complications of DM Severe and recurrent hypoglycemia Severe and prolonged hyperglycemia Acute Side-effects of treatment regimens Improve quality of work for care-givers
9 Higher risk of Acute Complications Hyperglycemia ( > 14 mmol/l) Impaired renal function Decrease in thirst drive Acute changes in volume status Hypoglycemia (< 4.0 mmol/l) Decrease in hypoglycemia awareness Associated cognitive impairment Risk of falls fractures 1 Increase risk of Mortality 2 1. JCEM 86: , 2. ACCORD, NEJM 2008
10 Glucose Targets in Older Adults with Type 2 diabetes
11 A1C Average BG (3 months) weighted to the past month Limitations
12 Other limitations to A1C Hemoglobinopathies Sickle cell or Thalassemia trait Large blood loss Transfusions Low hemoglobin and low hematocrit may result in inaccurate A1C levels May be due to renal disease Alternate testing: Fructosamine, past 4-21 days BG control
13 CDA Glycemic Targets 2008 For most patients A1C (%) 7.0 (< 6.5% to lower nephropathy if can be safely done) Preprandial PG (mmol/l) 2-h postprandial PG (mmol/l) (5-8 if A1c not achieved with above) Elderly. In people with multiple comorbidities, a high level of functional dependency and limited life expectancy, the goal should be less stringent, and clinicians should try to avoid symptoms of hyperglycemia and prevent hypoglycemia CDA CPG 2008
14 Intensive Glycemic Control - RCTs UKPDS: Mean age 54 (N=3867) 1 A1C 7% vs 7.9% 37% reduction in microvascular complications 21% reduction in any endpoint related to DM ADVANCE: Mean age 66 (N=11140) 2 32% CVD at baseline A1C 6.5% vs 7.3% No difference in retinopathy, CVD or mortality VADT: Mean age 60 (N=1792) 3 40% CV events A1C 6.9% vs 8.4% No significant difference in CVD or microvascular complications 1. Lancet 325:837-53, 1998, 2.NEJM NEJM 2009
15 Intensive Glycimic Control - RCTs ACCORD: Mean Age 62 (N=10251) 1 35% CV events at baseline A1C 6.4 % vs 7.5 % Increase risk of death from CV disease and all cause mortality Hypoglycemia in ACCORD 2 Intensive glycemic control results in increase rate of severe hypoglycemia (glucose < 2.8 mmo/l ) Patients with T2DM who have severe hypoglycemia are at increase risk of death regardless of intensity of glucose control 1. NEJM 2008, 2. BMJ 339:B
16 Diabetes and Aging Study Retrospective cohort study (2004-8) N = 71,092 - T2DM age > 60 Identify glycemic levels with the lowest rates of complications and mortality in older patients Mortality had a U-Shape relationship with A1C Suggest: setting an A1C < 8 % and caution that A1C <6 % were associated with increased mortality Diab Care 34(6):
17 Glycemic Targets DM GUIDELINES FOR GERIATRIC PATIENTS
18 Guidelines American Geriatric Society The American Geriatrics Society recommends a slightly higher A1C for certain groups: for frail older adults, persons with life expectancy of less than 5 years, and others in whom the risks of intensive glycemic control appear to outweigh the benefits, a less stringent target such as A1C 8% is appropriate. JAGS 51:S265 S280,
19 Guidelines: Veterans Affairs & DoD Major Comorbidities or Physiological Age Absent (>15 years of life expectancy) Present 5 to 15 years of life expectancy Marked < 5 years of life expectancy Microvascular Complications Absent or Mild Moderate Advanced 7 % <8% <9% < 8% <8% <9% <9% <9% <9% 1.VA/DoD Clinical Practice Guideline for The Management of DM
20 European Union Geriatric CPG European Diabetes Working Party for Older People. ( ). CPG for type 2 diabetes mellitus
21 Glycemic Targets FPG or preprandial PG CPG Frail elderly Consider 4-7 mmol/l mmol/l 2 2 hours postprandial mmol/l ( 5-8 if A1C target not met) In the low teens (< 14 mmol/l) 1 A1C (%) < 7% (< 6.5% to lower nephropathy if can be safely done) < 8% 2 1. Canadian Diabetes Association 2008 Clinical Practice Guidelines 2. European Union Geriatric Society 2004, American Geriatic Society 2003, VA DoD 2010
22 Goals of Treatment Reduce fluctuations in glucose levels Avoid hypoglycemia when possible Choose OHA with less risk of hypoglycemia as your second line of therapy after Metformin Start with low dose of OHAs and titrate slowly Adjust dose of medication as renal function deteriorates TREAT the PATIENT and NOT the NUMBERS
23 Type 2 DM Oral Agents Start with metformin in obese older adult: check renal and hepatic function avoid if Cr Cl below 30 ml/min Start with insulin secretagogue in lean older adult: gliclazide preferred to glyburide gliclazide MR for those who can swallow tablet whole choose repaglinide in those with irregular eating habit and renal impairment CDA Clinical Practice Guideline 2008
24 Type 2 DM Oral Agents Start with the lowest dose (Half the starting dose) and titrate slowly Starting doses: Gliclazide MR 30 mg daily Repaglinide 0.5 mg od-tid Metfromin 500 mg od
25 Type 2 DM Oral Agents Second or third line of therapy DPP4 inhibitors (sitagliptin, saxagliptin) Advantage low risk of hypoglycemia Need to have reasonable renal function (egfr >50) α-glucosidase inhibitor (acarbose) Improve post-prandial control Increase GI symptoms Avoid TZD in elderly specially with cardiac history
26
27 Insulin in Elderly Basal Insulin once daily Analog basal insulins are associated with less hypoglycemia Lantas or Levemir PreMix insulin bid Novolin 30/70 NovoMix 30 or Humalog Mix 25 Multiple daily injections: Short acting insulin with meals (Humalog, Novorapid, Apidra) Basal insulin at bedtime (Lantus or Levemir)
28 Three step approach 1>>>> Get Fasting to Target (<9) 2>>>> Get ac meals to Target (7-9) 3>>>> Get pc meals to Target (<14) **>>>> Always eliminate lows (<5)
29 Pattern Management Watch pattern of BG levels for 2-3 days A pattern consists of BG trend that occurs at the same time of day for at least 2 days Pick problematic areas, address hypoglycemia first then hyperglycemia To correct hyperglycemia, usually aim for fasting levels first, then premeal levels To asses overnight control, check BG at 3:00 am to rule out morning hyperglycemia caused by rebound. CDA: Building competency in diabetes education: advanced practice. 2003:2-41
30 Sliding scale insulin - bad Sliding scale insulin without a basal insulin is purely REACTIVE and allows for hyperglycemia Not a reliable means of glycemic control in the hospital setting Queale WS. et al. Arch Int Med 1997;157 30
31 Supplemental scale good! Supplements BASELINE insulin Adjust the baseline insulin or OHA first EXTRA analog bolus insulin ac meals ONLY CORRECTS hyperglycemia Can use supplemental needs to reassess BASELINE doses Adjust BASELINE insulin first before adding supplemental scale!! 31
32 Plans for Sick Day Management Adjustment of OHAs or insulin at the onset of acute illness If hypreglycemia consider % increase in dose of insulin Pay special attention to hydration Adjust CHO intake accordingly Prevent hospitalization
33 Hypoglycemia Treatment (BG<4) Inform patients of symptoms of hypogylcemia rule Glucose tabs (each tablet = 5 g) 15 g of glucose if mild to moderate symptoms. Repeat glucose measurement in 15 minutes Once the blood glucose is within target, the person should have the usual snack or meal, or if this is more than 1 hour away, a snack should be taken:
34 Hypoglycemia Examine both A1C and CBGM results Assess eating patterns If on insulin secretagogue, reduce dose and/or frequency Assess renal function If on insulin reduce dose by percent If on metformin alone, hypoglycemia is rare but possible (over suppression of glucagon) reduce dose and/or frequency
35 Glycemic Targets Targets: A1C % FBG & pre meal BG: mmol/l pc meals: < 14 mmol/l CBGM bid while adjusting dose
36 Conclusion In frail elderly with multiple co-morbidities and limited life expectancy there are no evidence to support tight glycemic control Risk of hypoglycemia is increased in this population and could be associated with adverse outcomes Set a appropriate glycemic target to avoid acute complications of DM Additional studies are needed to evaluate higher A1C targets in elderly populations
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationPresented By: Dr. Nadira Husein
Presented By: Dr. Nadira Husein I have no conflict of interest Disclosures I have received honoraria/educational grants from the following: Novo Nordisk, Eli Lilly, sanofi-aventis, Novartis, Astra Zeneca,
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationManagement of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)
Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the
More informationTherapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2
Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick
More informationChallenges in Glycemic Control in Adult and Geriatric Patients. Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner
Challenges in Glycemic Control in Adult and Geriatric Patients Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner Provide an overview of diabetes prevalence; discuss challenges and barriers
More informationWhen and how to start insulin: strategies for success in type 2 diabetes
1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology
More informationInsulin use in Type 2 Diabetes. Dr Rick Cutfield. Why? When? How?
Insulin use in Type 2 Diabetes Dr Rick Cutfield Why? When? How? 1 Conflict of Interest I have been on advisory boards or had speaker fees from the following pharmaceutical companies: - Eli Lilly - Novo
More informationWorkshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Authors: Dr. M. Love, Kathy Harrigan Reviewers:
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated March 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationInsulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types
Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationManaging Patients Newly Diagnosed with Diabetes. Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON
Managing Patients Newly Diagnosed with Diabetes Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON 1 Conflict Disclosure Information Conflict Disclosure Information
More informationInsulin Initiation and Intensification
Insulin Initiation and Intensification ANDREW S. RHINEHART, MD, FACP, CDE MEDICAL DIRECTOR AND DIABETOLOGIST JOHNSTON MEMORIAL DIABETES CARE CENTER Objectives Understand the pharmacodynamics and pharmacokinetics
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationDiabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
More informationStarting Insulin. Disclosures. Starting Insulin. Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres
Starting Insulin Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres Disclosures Scientific Consultant Abbott, AstraZeneca, GSK, Merck, Sanofi-Aventis, Janssen- Ortho, Servier
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
PL Detail-Document #300128 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Initiation and Adjustment of Insulin Regimens for Type
More informationDiabetes Fundamentals
Diabetes Fundamentals Prevalence of Diabetes in the U.S. Undiagnosed 10.7% of all people 20+ 23.1% of all people 60+ (12.2 million) Slide provided by Roche Diagnostics Sources: ADA, WHO statistics Prevalence
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationBASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS
BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS C O N T A C T D I A B E T E S S E R V I C E S F O R M O R E I N F O R M A T I O N 8 4 7-9 1 7-6 9 0 7 THIS SLIDE PRESENTATION WAS PREPARED BY SUE DROGOS,
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationA new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration
of nurse A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration 1. Check times for point of care meter blood glucose testing. Pre-Breakfast
More informationInsulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net
Insulin: Breaking Barriers Enhancing Therapies Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Questions To Address Who are candidates for insulin? When do we start insulin? How do the different types of
More informationA Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or
A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl
More informationInsulin/Diabetes Calculations
Insulin/Diabetes Calculations Dr. Aipoalani St Lukes Endocrinology Goals Describe various calculations for insulin dosing Understand importance of the total daily dose (TDD) of insulin Be able to calculate
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationThe Canadian Diabetes Association s 2013 Clinical Practice Guidelines and the Pharmacist Rob Roscoe, B.Sc.Pharm., ACPR, CDE, CPT
Welcome! Thank you for joining the webinar: The Canadian Diabetes Association s 2013 Clinical Practice Guidelines and the Pharmacist Rob Roscoe, B.Sc.Pharm., ACPR, CDE, CPT The webinar will begin shortly.
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationInsulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB
Insulin switch & Algorithms Rotorua GP CME June 2011 Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Goal of workshop Insulin switching make the necessary move Ensure participants are confident with Recognising
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationIntensifying Insulin In Type 2 Diabetes
Intensifying Insulin In Type 2 Diabetes Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine University of North Dakota School of Medicine and Health Sciences Assistant
More informationResident s Guide to Inpatient Diabetes
Resident s Guide to Inpatient Diabetes 1. All patients with diabetes of ANY TYPE, regardless of reason for admission, must have a Hemoglobin A1C documented in the medical record within 24 hours of admission
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationManaging Diabetes in the Athletic Population
Managing Diabetes in the Athletic Population Michael Prybicien, LA, ATC, CSCS, CES, PES Athletic Trainer, Passaic High School Overlook Medical Center & Adjunct Faculty, William Paterson University Dedicated
More informationAdd: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above
Guidelines for Type Diabetes - Diagnosis Fasting Plasma Glucose (confirm results if borderline) HbAIC Normal FPG < 00 < 5.5 Impaired Fasting Glucose (IFG) 00 to < 5.7%-.5% Diabetes Mellitus (or random
More informationTreatment Approaches to Diabetes
Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationInitiating & titrating insulin & switching in General Practice Workshop 1
Initiating & titrating insulin & switching in General Practice Workshop 1 Workshop goal To make participants comfortable in the timely initiation and titration of insulin Progression of Type 2 Diabetes
More informationMeasure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care
Measure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationDiabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW
Diabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW IT`S HARD TO GIVE GENERAL ADVICE! ``The Elderly`` Heterogeneous group ;widely varying
More informationInsulin onset, peak and duration of action
Insulin onset, peak and duration of action Insulin was first discovered in the early 190 s. Before then, diabetes could not be treated. Insulin was then taken from cow and pig pancreases, but nearly all
More informationDiabetes Dispatch. Children with Type 2 Diabetes: How do we treat them? A L A S K A N A T I V E D I A B E T E S T E A M. Inside this issue:
A L A S K A N A T I V E D I A B E T E S T E A M Diabetes Dispatch Volume 8, Issue 1 Spring 2013 Compiled by Justin Park, Pharm.D. Candidate Type 2 diabetes is a relatively new disease in children and adolescents.
More information2. What Should Advocates Know About Diabetes? O
2. What Should Advocates Know About Diabetes? O ften a school district s failure to properly address the needs of a student with diabetes is due not to bad faith, but to ignorance or a lack of accurate
More informationOverview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health
Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationMary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes
Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Objectives Pathophysiology of Diabetes Acute & Chronic Complications Managing acute emergencies Case examples 11/24/2014 UWHealth
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationDiabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th 2013. Presenter: Derek Sanders, D.Ph.
Diabetes and the Elimination of Sliding Scale Insulin Date: April 30 th 2013 Presenter: Derek Sanders, D.Ph. Background Information Epidemiology and Risk Factors Diabetes Its Definition and Its Impact
More informationType 2 diabetes Definition
Type 2 diabetes Definition Type 2 diabetes is a lifelong (chronic) disease in which there are high levels of sugar (glucose) in the blood. Type 2 diabetes is the most common form of diabetes. Causes Diabetes
More informationEpidemiology of Diabetes (US data released 1/26/2011)
Therapy in Diabetes Mellitus Part 1 Lekshmi T. Nair, MD, MHS Assistant Professor Department of Internal Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio State University Wexner Medical
More informationImproving drug prescription in elderly diabetic patients. FRANCESC FORMIGA Hospital Universitari de Bellvitge
Improving drug prescription in elderly diabetic patients FRANCESC FORMIGA Hospital Universitari de Bellvitge High prevalence, but also increases the incidence. The older the patients, the higher the percentages
More informationManaging the Hospitalized Patient on Insulin: Care Transition. Catie Prinzing MSN, APRN, CNS
Managing the Hospitalized Patient on Insulin: Care Transition Catie Prinzing MSN, APRN, CNS Diabetes and Hospitalization People with DM are hospitalized 3x more frequently than patients without diabetes
More informationGuidelines. for Sick Day Management for People with Diabetes
Guidelines for Sick Day Management for People with Diabetes When to Follow Sick Day Guidelines These guidelines apply when the person with diabetes is feeling unwell or noticing signs of an illness and/
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationTYPE2DIABETES INSULIN TREATMENT 2009 UPDATE ON A HEALTHCARE PROFESSIONAL S GUIDE TO TREATMENT BY J. ROBIN CONWAY, MD. www.diabetesclinic.
TYPE2DIABETES INSULIN TREATMENT 2009 UPDATE ON A HEALTHCARE PROFESSIONAL S GUIDE TO TREATMENT BY J. ROBIN CONWAY, MD www.diabetesclinic.ca Author: Dr. Robin Conway Note to readers The contents herein represent
More informationUser guide Basal-bolus Insulin Dosing Chart: Adult
Contacts and further information Local contact Clinical pharmacy or visiting pharmacy Diabetes education service Director of Medical Services Visiting or local endocrinologist or diabetes physician For
More informationInsulin pen start checklist
Insulin pen start checklist Topic Instruction Date & Initials 1. Cognitive Assessment 2. Insulin Delivery loading appropriate mixing priming shot dialing up dose delivery of insulin 3. Insulin type/action
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
Page 1 of 5 PURPOSE To assure that DOP inmates with Diabetes, who require insulin therapy, are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers are to follow
More informationLead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of:
Guideline for members of the diabetes team and dietetic department for advising on insulin dose adjustment and teaching the skills of insulin dose adjustment to adults with type 1 or type 2 diabetes mellitus
More informationUpdate on the management of Type 2 Diabetes
Update on the management of Type 2 Diabetes Mona Nasrallah M.D Assistant Professor, Endocrinology American University of Beirut 10 th Annual Family Medicine Conference October 14,2011 Global Prevalence
More informationInformation for Patients
Information for Patients Guidance for Diabetic Persons having bowel preparation for a flexible sigmoidoscopy or a colonoscopy or a combined gastroscopy and colonoscopy This guidance is provided to assist
More informationTYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES
TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES Non-insulin regimes Basal insulin only (usually with oral agents) Number of injections 1 Regimen complexity Low Basal insulin +1 meal-time rapidacting insulin
More informationThe first injection of insulin was given on
EFFECTIVE USE OF INSULIN THERAPY IN TYPE 2 DIABETES * Bernard Zinman, MDCM ABSTRACT Type 2 diabetes is a progressive disease; an individual s ability to secrete insulin in increasing amounts to overcome
More informationApproximate Cost Reference List i for Antihyperglycemic Agents
Alpha Glucosidase Inhibitor Acarbose (Glucobay ) Biguanides Metformin (Glucophage, generic) Metformin ER (Glumetza ) Approximate Cost Reference List i for Antihyperglycemic Agents Incretin Agents - DPP-4
More informationType 2 Diabetes Mellitus and Insulin resistance syndrome in Children
Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationCauses, incidence, and risk factors
Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationOverview and update of modern type 2 Diabetes philosophy and management. Dr Steve Stanaway Consultant Endocrinologist BCU
Overview and update of modern type 2 Diabetes philosophy and management Dr Steve Stanaway Consultant Endocrinologist BCU Diabetes economics 2009: 2.6M adults with DM in UK (90% type 2) 2025: est. > 4M
More informationUnderstanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationSUBJECT: DIABETES MEDICATION MANAGEMENT PROTOCOLS
SUBJECT: DIABETES MEDICATION MANAGEMENT PROTOCOLS PURPOSE To establish a process that will enable Certified Diabetes Educators (CDE) and/or staff with Board Certification in Advanced Diabetes Management
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Incretin Mimetic/Enhancer Hypoglycemics (formerly referred to as Other Hypoglycemics) A. Thresholds for Prior Authorization All prescriptions
More informationIndividualizing Diabetes Care for Long Term Care Residents: A Guidebook. Practical information for diabetes management in Long Term care settings
Individualizing Diabetes Care for Long Term Care Residents: A Guidebook Practical information for diabetes management in Long Term care settings Created by: Long Term Care Working Group Of Health Care
More informationPrescribing for type 2 diabetes in the elderly: issues and solutions
Prescribing for type 2 diabetes in the elderly: issues and solutions Roger Gadsby MBE, BSc, DRCOG, DCH, FRCGP Debbie Hicks MSc, BA, RGN, NMP, DN Cert, PWT Cert Richard Holt MA, PhD, FRCP, FHEA Over half
More informationCLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies
Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin
More informationCOST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL
Malaysian Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 19 23 (2007) COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL TRI MURTI ANDAYANI* AND IKE IMANINGSIH
More informationDiabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
More informationINTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL
INTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL Presented by: Leyda Callejas PGY5 Endocrinology, Diabetes and Metabolism Acknowledgements: Dr. P Orlander Dr. V Lavis Dr. N Shah
More informationTreatment of Type 2 Diabetes
Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored
More informationThere seem to be inconsistencies regarding diabetic management in
Society of Ambulatory Anesthesia (SAMBA) Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Review of the consensus statement and additional
More informationIntroduction. We hope this guide will aide you and your staff in creating a safe and supportive environment for your students challenged by diabetes.
Introduction Diabetes is a chronic disease that affects the body s ability to metabolize food. The body converts much of the food we eat into glucose, the body s main source of energy. Glucose is carried
More informationInsulin therapy in type 2 diabetes When and how? Disclosures. Learning Objectives. None relevant to today s talk
Insulin therapy in type 2 diabetes When and how? Cecilia C Low Wang, MD Univ Colorado AMC SOM Department of Medicine Division of Endocrinology, Metabolism, and Diabetes Disclosures None relevant to today
More informationTeaching Self-Management of Diabetes Colin Reeve, BSP, CDE
Welcome! Thank you for joining the webinar: Teaching Self-Management of Diabetes Colin Reeve, BSP, CDE The webinar will begin shortly. Please ensure that your computer speakers are turned on If you experience
More informationType 1 and Type 2 Diabetes in Pediatric Practice
Type 1 and Type 2 Diabetes in Pediatric Practice Chirag R. Kapadia, MD Division of Endocrinology, Phoenix Children s Hospital Clinical Assistant Professor, U of A College of Medicine Presentation outline
More informationGlycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol
Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding
More informationInsulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.
Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More information81 Central Street, Houghton Estate, 2198 PO Box 2900, Saxonwold, 2132 www.cdediabetes.co.za
81 Central Street, Houghton Estate, 2198 PO Box 2900, Saxonwold, 2132 www.cdediabetes.co.za Clinical Guidelines 2015 The Use of Antibody Testing in the Management of Diabetes Mellitus When should the Antibody
More information